Bronchopulmonary Dysplasia - Pipeline Review, H1 2014

Global Markets Direct
April 30, 2014
54 Pages - GMD12064
$2,000.00

Summary

Global Markets Direct’s, ‘Bronchopulmonary Dysplasia - Pipeline Review, H1 2014’, provides an overview of the Bronchopulmonary Dysplasia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bronchopulmonary Dysplasia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bronchopulmonary Dysplasia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bronchopulmonary Dysplasia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Bronchopulmonary Dysplasia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Bronchopulmonary Dysplasia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Bronchopulmonary Dysplasia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Bronchopulmonary Dysplasia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Bronchopulmonary Dysplasia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

'

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Bronchopulmonary Dysplasia Overview 6
Therapeutics Development 7
Pipeline Products for Bronchopulmonary Dysplasia - Overview 7
Pipeline Products for Bronchopulmonary Dysplasia - Comparative Analysis 8
Bronchopulmonary Dysplasia - Therapeutics under Development by Companies 9
Bronchopulmonary Dysplasia - Therapeutics under Investigation by Universities/Institutes 11
Bronchopulmonary Dysplasia - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Bronchopulmonary Dysplasia - Products under Development by Companies 15
Bronchopulmonary Dysplasia - Products under Investigation by Universities/Institutes 16
Bronchopulmonary Dysplasia - Companies Involved in Therapeutics Development 17
Chiesi Farmaceutici SpA 17
MediPost Co., Ltd. 18
Syntrix Biosystems, Inc. 19
Ikaria Inc. 20
Clarassance, Inc. 21
Bronchopulmonary Dysplasia - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 26
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
Inomax - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Pneumostem - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
budesonide - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
CG-100 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Small Molecules to Inhibit RAR-Gamma for Emphysema and Bronchopulmonary Dysplasia - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Nanocurcumin - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
SX-682 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
R-100 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Bronchopulmonary Dysplasia - Recent Pipeline Updates 45
Bronchopulmonary Dysplasia - Dormant Projects 46
Bronchopulmonary Dysplasia - Discontinued Products 47
Bronchopulmonary Dysplasia - Product Development Milestones 48
Featured News & Press Releases 48
Feb 06, 2014: Stem cells to treat lung disease in preterm infants 48
Dec 04, 2012: Discovery Labs Announces Presentation Of Surfaxin Pharmacoeconomic Analysis Data At 2012 Hot Topics In Neonatology Annual Meeting 48
Sep 26, 2012: Medipost Receives KFDA Approval For Phase II Clinical Trial Of Lung Disease Medicine Pneumostem 50
May 31, 2012: Medipost Submits Application To KFDA For Pneumostem Clinical Trial 50
Feb 27, 2012: Ikaria Completes Patient Enrollment In Pivotal Phase III Trial For Bronchopulmonary Dysplasia 51
Jan 05, 2011: Ikaria Receives Marketing Exclusivity Extension For Inomax From FDA 51
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 54
Disclaimer 54

List of Tables
Number of Products under Development for Bronchopulmonary Dysplasia, H1 2014 7
Number of Products under Development for Bronchopulmonary Dysplasia - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 10
Number of Products under Investigation by Universities/Institutes, H1 2014 11
Comparative Analysis by Late Stage Development, H1 2014 12
Comparative Analysis by Clinical Stage Development, H1 2014 13
Comparative Analysis by Early Stage Development, H1 2014 14
Products under Development by Companies, H1 2014 15
Products under Investigation by Universities/Institutes, H1 2014 16
Bronchopulmonary Dysplasia - Pipeline by Chiesi Farmaceutici SpA, H1 2014 17
Bronchopulmonary Dysplasia - Pipeline by MediPost Co., Ltd., H1 2014 18
Bronchopulmonary Dysplasia - Pipeline by Syntrix Biosystems, Inc., H1 2014 19
Bronchopulmonary Dysplasia - Pipeline by Ikaria Inc., H1 2014 20
Bronchopulmonary Dysplasia - Pipeline by Clarassance, Inc., H1 2014 21
Assessment by Monotherapy Products, H1 2014 22
Number of Products by Stage and Target, H1 2014 25
Number of Products by Stage and Mechanism of Action, H1 2014 28
Number of Products by Stage and Route of Administration, H1 2014 30
Number of Products by Stage and Molecule Type, H1 2014 32
Bronchopulmonary Dysplasia Therapeutics - Recent Pipeline Updates, H1 2014 45
Bronchopulmonary Dysplasia - Dormant Projects, H1 2014 46
Bronchopulmonary Dysplasia - Discontinued Products, H1 2014 47

List of Figures
Number of Products under Development for Bronchopulmonary Dysplasia, H1 2014 7
Number of Products under Development for Bronchopulmonary Dysplasia - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Clinical Stage Development, H1 2014 13
Comparative Analysis by Early Stage Products, H1 2014 14
Assessment by Monotherapy Products, H1 2014 22
Number of Products by Top 10 Target, H1 2014 23
Number of Products by Stage and Top 10 Target, H1 2014 24
Number of Products by Top 10 Mechanism of Action, H1 2014 26
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 27
Number of Products by Top 10 Route of Administration, H1 2014 29
Number of Products by Stage and Top 10 Route of Administration, H1 2014 30
Number of Products by Top 10 Molecule Type, H1 2014 31
Number of Products by Stage and Top 10 Molecule Type, H1 2014 32

$2,000.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Custom Research

Need a custom report
tailored to your goals and budget? 

E-mail us your project outline
or call Client Services to speak
with your industry analyst.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Discount Codes

Request Discount Codes
for reports of interest to you.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax